UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 15, 2012
INCYTE CORPORATION
(Exact name of registrant as specified in its charter)
|
Delaware (State or Other Jurisdiction of |
|
0-27488 (Commission File Number) |
|
94-3136539 (I.R.S. Employer |
|
Experimental Station |
|
|
|
Route 141 & Henry Clay Road |
|
|
|
Building E336 |
|
|
|
Wilmington, DE |
|
19880 |
|
(Address of principal executive offices) |
|
(Zip Code) |
(302) 498-6700
(Registrant’s telephone number,
including area code)
N/A
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 Other Events.
On November 15, 2012, Incyte Corporation (the “Company”) announced that it had earned a $50.0 million milestone payment pursuant to the License, Development and Commercialization Agreement dated as of December 18, 2009, by and between the Company and Eli Lilly and Company. Achievement of the milestone payment was related to the initiation of the Phase III program for baricitinib (LY3009104) for the treatment of rheumatoid arthritis.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Dated: November 15, 2012 |
| |
|
|
| |
|
|
INCYTE CORPORATION | |
|
|
| |
|
|
| |
|
|
By: |
/s/ Eric H. Siegel |
|
|
|
Eric H. Siegel |
|
|
|
Executive Vice President and General Counsel |